Prevalence of Unexplained Left Ventricular Hypertrophy by Cardiac Magnetic Resonance Imaging in MESA

Daniele Massera, Robyn L. McClelland, Bharath Ambale-Venkatesh, Antoinette S. Gomes, W. Gregory Hundley, Nadine Kawel-Boehm, Kihei Yoneyama, David S. Owens, Mario J. Garcia, Mark V. Sherrid, Jorge Kizer, Joao A.C. Lima, David A. Bluemke

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background Hypertrophic cardiomyopathy is defined as unexplained left ventricular ( LV ) hypertrophy (wall thickness ≥15 mm) and is prevalent in 0.2% of adults (1:500) in population-based studies using echocardiography. Cardiac magnetic resonance imaging ( MRI ) allows for more accurate wall thickness measurement across the entire ventricle than echocardiography. The prevalence of unexplained LV hypertrophy by cardiac MRI is unknown. MESA (Multi-Ethnic Study of Atherosclerosis) recruited individuals without overt cardiovascular disease 45 to 84 years of age. Methods and Results We studied 4972 individuals who underwent measurement of regional LV wall thickness by cardiac MRI as part of the MESA baseline exam. American Heart Association criteria were used to define LV segments. We excluded participants with hypertension, LV dilation (≥95% predicted end-diastolic volume) or dysfunction (ejection fraction ≤50%), moderate-to-severe left-sided valve lesions by cardiac MRI , severe aortic valve calcification by cardiac computed tomography (aortic valve Agatston calcium score >1200 in women or >2000 in men), obesity (body mass index >35 kg/m2), diabetes mellitus, and current smoking. Sixty-seven participants (aged 64±10 years, 9% female) had unexplained LV hypertrophy (wall thickness ≥15 mm in at least 2 adjacent LV segments), representing 1.4% (1 in 74) participants, 2.6% of men and 0.2% of women. Prevalence was similar across categories of race/ethnicity. Hypertrophy was focal in 17 (25.4%), intermediate in 44 (65.7%), and diffuse in 5 (7.5%) participants. Conclusions The prevalence of unexplained LV hypertrophy in a population-based cohort using cardiac MRI was 1.4%. This may have implications for the diagnosis of patients with hypertrophic cardiomyopathy and will require further study.

Original languageEnglish (US)
Pages (from-to)e012250
JournalJournal of the American Heart Association
Volume8
Issue number8
DOIs
StatePublished - Apr 16 2019

Fingerprint

Left Ventricular Hypertrophy
Atherosclerosis
Magnetic Resonance Imaging
Hypertrophic Cardiomyopathy
Echocardiography
Heart Valves
Aortic Valve
Hypertrophy
Population
Dilatation
Diabetes Mellitus
Body Mass Index
Cardiovascular Diseases
Obesity
Smoking
Tomography
Hypertension
Calcium

Keywords

  • hypertrophic cardiomyopathy
  • magnetic resonance imaging
  • population‐based study

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Massera, D., McClelland, R. L., Ambale-Venkatesh, B., Gomes, A. S., Hundley, W. G., Kawel-Boehm, N., ... Bluemke, D. A. (2019). Prevalence of Unexplained Left Ventricular Hypertrophy by Cardiac Magnetic Resonance Imaging in MESA. Journal of the American Heart Association, 8(8), e012250. https://doi.org/10.1161/JAHA.119.012250

Prevalence of Unexplained Left Ventricular Hypertrophy by Cardiac Magnetic Resonance Imaging in MESA. / Massera, Daniele; McClelland, Robyn L.; Ambale-Venkatesh, Bharath; Gomes, Antoinette S.; Hundley, W. Gregory; Kawel-Boehm, Nadine; Yoneyama, Kihei; Owens, David S.; Garcia, Mario J.; Sherrid, Mark V.; Kizer, Jorge; Lima, Joao A.C.; Bluemke, David A.

In: Journal of the American Heart Association, Vol. 8, No. 8, 16.04.2019, p. e012250.

Research output: Contribution to journalArticle

Massera, D, McClelland, RL, Ambale-Venkatesh, B, Gomes, AS, Hundley, WG, Kawel-Boehm, N, Yoneyama, K, Owens, DS, Garcia, MJ, Sherrid, MV, Kizer, J, Lima, JAC & Bluemke, DA 2019, 'Prevalence of Unexplained Left Ventricular Hypertrophy by Cardiac Magnetic Resonance Imaging in MESA', Journal of the American Heart Association, vol. 8, no. 8, pp. e012250. https://doi.org/10.1161/JAHA.119.012250
Massera, Daniele ; McClelland, Robyn L. ; Ambale-Venkatesh, Bharath ; Gomes, Antoinette S. ; Hundley, W. Gregory ; Kawel-Boehm, Nadine ; Yoneyama, Kihei ; Owens, David S. ; Garcia, Mario J. ; Sherrid, Mark V. ; Kizer, Jorge ; Lima, Joao A.C. ; Bluemke, David A. / Prevalence of Unexplained Left Ventricular Hypertrophy by Cardiac Magnetic Resonance Imaging in MESA. In: Journal of the American Heart Association. 2019 ; Vol. 8, No. 8. pp. e012250.
@article{9f1d889e18cf4155b7936d4b49b0a9fe,
title = "Prevalence of Unexplained Left Ventricular Hypertrophy by Cardiac Magnetic Resonance Imaging in MESA",
abstract = "Background Hypertrophic cardiomyopathy is defined as unexplained left ventricular ( LV ) hypertrophy (wall thickness ≥15 mm) and is prevalent in 0.2{\%} of adults (1:500) in population-based studies using echocardiography. Cardiac magnetic resonance imaging ( MRI ) allows for more accurate wall thickness measurement across the entire ventricle than echocardiography. The prevalence of unexplained LV hypertrophy by cardiac MRI is unknown. MESA (Multi-Ethnic Study of Atherosclerosis) recruited individuals without overt cardiovascular disease 45 to 84 years of age. Methods and Results We studied 4972 individuals who underwent measurement of regional LV wall thickness by cardiac MRI as part of the MESA baseline exam. American Heart Association criteria were used to define LV segments. We excluded participants with hypertension, LV dilation (≥95{\%} predicted end-diastolic volume) or dysfunction (ejection fraction ≤50{\%}), moderate-to-severe left-sided valve lesions by cardiac MRI , severe aortic valve calcification by cardiac computed tomography (aortic valve Agatston calcium score >1200 in women or >2000 in men), obesity (body mass index >35 kg/m2), diabetes mellitus, and current smoking. Sixty-seven participants (aged 64±10 years, 9{\%} female) had unexplained LV hypertrophy (wall thickness ≥15 mm in at least 2 adjacent LV segments), representing 1.4{\%} (1 in 74) participants, 2.6{\%} of men and 0.2{\%} of women. Prevalence was similar across categories of race/ethnicity. Hypertrophy was focal in 17 (25.4{\%}), intermediate in 44 (65.7{\%}), and diffuse in 5 (7.5{\%}) participants. Conclusions The prevalence of unexplained LV hypertrophy in a population-based cohort using cardiac MRI was 1.4{\%}. This may have implications for the diagnosis of patients with hypertrophic cardiomyopathy and will require further study.",
keywords = "hypertrophic cardiomyopathy, magnetic resonance imaging, population‐based study",
author = "Daniele Massera and McClelland, {Robyn L.} and Bharath Ambale-Venkatesh and Gomes, {Antoinette S.} and Hundley, {W. Gregory} and Nadine Kawel-Boehm and Kihei Yoneyama and Owens, {David S.} and Garcia, {Mario J.} and Sherrid, {Mark V.} and Jorge Kizer and Lima, {Joao A.C.} and Bluemke, {David A.}",
year = "2019",
month = "4",
day = "16",
doi = "10.1161/JAHA.119.012250",
language = "English (US)",
volume = "8",
pages = "e012250",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Prevalence of Unexplained Left Ventricular Hypertrophy by Cardiac Magnetic Resonance Imaging in MESA

AU - Massera, Daniele

AU - McClelland, Robyn L.

AU - Ambale-Venkatesh, Bharath

AU - Gomes, Antoinette S.

AU - Hundley, W. Gregory

AU - Kawel-Boehm, Nadine

AU - Yoneyama, Kihei

AU - Owens, David S.

AU - Garcia, Mario J.

AU - Sherrid, Mark V.

AU - Kizer, Jorge

AU - Lima, Joao A.C.

AU - Bluemke, David A.

PY - 2019/4/16

Y1 - 2019/4/16

N2 - Background Hypertrophic cardiomyopathy is defined as unexplained left ventricular ( LV ) hypertrophy (wall thickness ≥15 mm) and is prevalent in 0.2% of adults (1:500) in population-based studies using echocardiography. Cardiac magnetic resonance imaging ( MRI ) allows for more accurate wall thickness measurement across the entire ventricle than echocardiography. The prevalence of unexplained LV hypertrophy by cardiac MRI is unknown. MESA (Multi-Ethnic Study of Atherosclerosis) recruited individuals without overt cardiovascular disease 45 to 84 years of age. Methods and Results We studied 4972 individuals who underwent measurement of regional LV wall thickness by cardiac MRI as part of the MESA baseline exam. American Heart Association criteria were used to define LV segments. We excluded participants with hypertension, LV dilation (≥95% predicted end-diastolic volume) or dysfunction (ejection fraction ≤50%), moderate-to-severe left-sided valve lesions by cardiac MRI , severe aortic valve calcification by cardiac computed tomography (aortic valve Agatston calcium score >1200 in women or >2000 in men), obesity (body mass index >35 kg/m2), diabetes mellitus, and current smoking. Sixty-seven participants (aged 64±10 years, 9% female) had unexplained LV hypertrophy (wall thickness ≥15 mm in at least 2 adjacent LV segments), representing 1.4% (1 in 74) participants, 2.6% of men and 0.2% of women. Prevalence was similar across categories of race/ethnicity. Hypertrophy was focal in 17 (25.4%), intermediate in 44 (65.7%), and diffuse in 5 (7.5%) participants. Conclusions The prevalence of unexplained LV hypertrophy in a population-based cohort using cardiac MRI was 1.4%. This may have implications for the diagnosis of patients with hypertrophic cardiomyopathy and will require further study.

AB - Background Hypertrophic cardiomyopathy is defined as unexplained left ventricular ( LV ) hypertrophy (wall thickness ≥15 mm) and is prevalent in 0.2% of adults (1:500) in population-based studies using echocardiography. Cardiac magnetic resonance imaging ( MRI ) allows for more accurate wall thickness measurement across the entire ventricle than echocardiography. The prevalence of unexplained LV hypertrophy by cardiac MRI is unknown. MESA (Multi-Ethnic Study of Atherosclerosis) recruited individuals without overt cardiovascular disease 45 to 84 years of age. Methods and Results We studied 4972 individuals who underwent measurement of regional LV wall thickness by cardiac MRI as part of the MESA baseline exam. American Heart Association criteria were used to define LV segments. We excluded participants with hypertension, LV dilation (≥95% predicted end-diastolic volume) or dysfunction (ejection fraction ≤50%), moderate-to-severe left-sided valve lesions by cardiac MRI , severe aortic valve calcification by cardiac computed tomography (aortic valve Agatston calcium score >1200 in women or >2000 in men), obesity (body mass index >35 kg/m2), diabetes mellitus, and current smoking. Sixty-seven participants (aged 64±10 years, 9% female) had unexplained LV hypertrophy (wall thickness ≥15 mm in at least 2 adjacent LV segments), representing 1.4% (1 in 74) participants, 2.6% of men and 0.2% of women. Prevalence was similar across categories of race/ethnicity. Hypertrophy was focal in 17 (25.4%), intermediate in 44 (65.7%), and diffuse in 5 (7.5%) participants. Conclusions The prevalence of unexplained LV hypertrophy in a population-based cohort using cardiac MRI was 1.4%. This may have implications for the diagnosis of patients with hypertrophic cardiomyopathy and will require further study.

KW - hypertrophic cardiomyopathy

KW - magnetic resonance imaging

KW - population‐based study

UR - http://www.scopus.com/inward/record.url?scp=85064494250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064494250&partnerID=8YFLogxK

U2 - 10.1161/JAHA.119.012250

DO - 10.1161/JAHA.119.012250

M3 - Article

C2 - 30957681

AN - SCOPUS:85064494250

VL - 8

SP - e012250

JO - Journal of the American Heart Association

JF - Journal of the American Heart Association

SN - 2047-9980

IS - 8

ER -